Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants. This news comes as a surprise because, at the time of its IPO a mere two months ago, BioAge highlighted azelaprag’s potential in patients undergoing obesity therapy with incretin drugs. Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.